The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

WASHINGTON -- Moderna is applying for full government approval for its COVID-19 vaccine. The company said it is submitting trial data to the Food and Drug Administration on a rolling basis over the ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Moderna says the Food and Drug Administration has issued full approval for its COVID-19 vaccine for use in people aged 18 and older. The company made the announcement in a press release on Monday ...

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...

Dr. Anthony Fauci on Tuesday said that there's a chance that Moderna's COVID-19 booster shot may not have FDA and CDC approval by the White House's Sept. 20 target date, though he expects that ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while ...

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...